Abstract:The aureolic acid-type polyketide mithramycin (MTM) has a remarkable cytotoxicity against a variety of human tumors and has been used for the treatment of several types of cancer, including chronic and acute myeloid leukemia, testicular carcinoma, hypercalcemia, and Paget’s disease. However, its clinical use is quite limited due to its toxicity. Recently, interest in MTM has been renewed after its identification as a top candidate for the inhibition of the aberrant fusion transcription factor EWS-FLI1, associated with malignant transformation and progression of Ewing sarcoma tumor family. The mechanism of MTM inhibition involves its reversible non-intercalative interaction with GC-rich DNA regions. As a result of this binding, MTM blocks binding of transcription factors (such as Sp1) to their GC-rich promoters and inhibits transcription of several proto-oncogenes and thus suppresses various types of cancer. Knowledge of the biosynthesis of MTM and its gene cluster has enabled genetic modifications of the gene cluster and combinatorial biosynthesis to produce new modified MTM molecules (“mithralogues”) with improved efficacy and lower toxicity, which has also renewed interest in the clinical development of MTM. However, production yields of MTM and its analogues are low in the natural production strains. Recent developments in genetic engineering approaches have made it possible to increase MTM production through more rational strategies based on genetic manipulations and heterologous expression in optimized chassis. Recent construction of various genetically modified strains of Streptomyces lividans has shown their use for efficient heterologous production of various biologically active secondary metabolites including MTM.Key points• Discovery a novel bifunctional glycosyl hydrolase from uncultured microorganism.• Heterologous production of MTM in engineered S. lividans strains is efficient.

Self‐Resistance to an Antitumor Antibiotic: A DNA Glycosylase Triggers the Base‐Excision Repair System in Yatakemycin Biosynthesis

Yatakemycin biosynthesis requires two deoxyribonucleases for toxin self-resistance

The Rapid Emergence of Tigecycline Resistance in bla KPC-2 Harboring Klebsiella pneumoniae , as Mediated in Vivo by Mutation in tetA During Tigecycline Treatment.

Base excision repair system targeting DNA adducts of trioxacarcin/LL-D49194 antibiotics for self-resistance

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Depletion of 4E-Bp1 and Regulation of Autophagy Lead to Yxm110-Induced Anticancer Effects

Analysis of tigecycline resistance development in clinical Acinetobacter baumannii isolates through a combined genomic and transcriptomic approach

DNA topoisomerase-targeting antitumor drugs can be studied in yeast

Dual-Mechanism Confers Self-Resistance to the Antituberculosis Antibiotic Capreomycin

6-Dithio-2'-deoxyguanosine Analogs Induce Reactive Oxygen Species-Mediated Tumor Cell Apoptosis Via Bi-Targeting Thioredoxin 1 and Telomerase.

Design, Synthesis and Biological Evaluation of Biaryl Amide Derivatives As Modulators of Multi-Drug Resistance

Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds

Site-Directed Mutagenesis And Prelminary X-Ray Crystallographic Studies Of The Tabtoxin Resistance Protein

Discovery, enantioselective synthesis of myrtucommulone E analogues as tyrosyl-DNA phosphodiesterase 2 inhibitors and their biological activities

The antitumor antibiotic mithramycin: new advanced approaches in modification and production

Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects

A Secreted BBE-Like Enzyme Acting as a Drug-Binding Efflux Carrier Confers Microbial Self-Resistance to Mitomycin C

Identification of a novel DNA repair inhibitor using an in silico driven approach shows effective combinatorial activity with genotoxic agents against multidrug‐resistant Escherichia coli

Resistance and Phylogeny Guided Discovery Reveals Structural Novelty of Tetracycline Antibiotics

Checkpoint adaptation in recombination-deficient cells drives aneuploidy and resistance to genotoxic agents

Emerging High‐Level Tigecycline Resistance: Novel Tetracycline Destructases Spread via the Mobile Tet(X)